Development and performance of the c4c national clinical trial networks for optimizing pediatric trial facilitation

Introduction: The high failure rate of industry-driven pediatric clinical trials leads to insufficient timely labeling of drugs in children and a lack of scientific evidence, resulting in the persistently high off-label drug use. National clinical trial networks can facilitate collaboration between sites, investigators, and experts, increasing the likelihood of successful trials. Within the conect4children (c4c) network,…

The development of the Belgian paediatric clinical trial network

Paediatric clinical trials are critical to ensure that medications prescribed to children are safe and effective. However, evidence-based dosing and labelling of such medications remain limited, and most clinical trials in paediatrics fail. Factors for lack of trial completion include performance at site level (limited patient recruitment, limited site staff experience and lack of infrastructure),…

The development of the Belgian paediatric clinical trial network

Paediatric clinical trials are critical to ensure that medications prescribed to children are safe and effective. However, evidence-based dosing and labelling of such medications remain limited, and most clinical trials in paediatrics fail. Factors for lack of trial completion include performance at site level (limited patient recruitment, limited site staff experience and lack of infrastructure),…

c4c team: Ricardo Fernandes

Meet the team behind c4c! We are a diverse group of people from many different backgrounds, all working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Ricardo Fernandes, from the University of Lisbon and AIDFM.

End of Year Message

Dear Partners and Friends of conect4children,

At the end of a year which brought a lot of change and uncertainty to the world around us, we would like to reflect on c4c´s achievements of the past year and to look forward to what lies ahead in the coming months.

Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach

Patent ductus arteriosus (PDA) in preterm infants is associated with increased morbidities and mortality. Prophylactic treatment with cyclooxygenase inhibitors, as indomethacin or ibuprofen, failed to demonstrate significant clinical benefits. Acetaminophen may represent an alternative treatment option. To read full article, click here